Biohaven Ltd., formerly known as Biohaven Pharmaceutical Holding Company Ltd., officially launched Oct. 4 after an $11.6 billion acquisition deal with Pfizer closed.
Since then, Biohaven has been busy raising funds through a public offering that provided $301.9 million to fund operations. At launch, the company had $257.8 million in cash and no debt.
The company also brought on three new executives to lead its drug development efforts. They are Bruce Car, Ph.D., who joined in August from Agios Pharmaceuticals to serve as chief scientific officer; former Bristol Myers Squibb executive Irfan Qureshi, M.D., to be chief medical officer; and Tanya Fischer, M.D., Ph.D., as chief development officer and head of translational medicine. Fischer previously held the role of vice president of CNS development at Alnylam Pharmaceuticals where she expanded the CNS pipeline.